Table 4.
Joint effect of HPV16 serology and the combined risk genotypes of TNF-α SNPs on risk of OSCC
|
Risk groups1 |
HPV16 status |
Patients |
Controls |
Adjusted OR (95% CI)2 |
||||
|---|---|---|---|---|---|---|---|---|
| |
|
(n = 325) |
(n = 335) |
|
||||
| No. | % | No. | % | OSCC | SCCOP | Oral cavity | ||
| Low-risk group |
− |
61 |
18.8 |
81 |
24.2 |
1.0 |
1.0 |
1.0 |
| Medium-risk group |
− |
53 |
16.3 |
129 |
38.5 |
1.0 (0.3 − 1.0) |
1.0 (0.3 − 1.1) |
0.5 (0.3 − 1.0) |
| High-risk group |
− |
111 |
34.2 |
83 |
24.8 |
1.8 (1.1 − 2.8) |
1.8 (1.0 − 3.3) |
1.6 (0.9 − 2.8) |
| Low-risk group |
+ |
27 |
8.3 |
13 |
3.9 |
1.5 (1.0 − 2.9) |
2.9 (1.4 − 6.2) |
0.7 (0.2 − 2.4) |
| Medium-risk group |
+ |
23 |
7.1 |
21 |
6.3 |
2.7 (1.3 − 5.8) |
4.9 (2.2 − 11.2) |
0.2 (0.0 − 1.0) |
| High-risk group | + | 50 | 15.4 | 8 | 2.4 | 8.5 (3.7 − 19.4) | 15.8 (6.5 − 38.0) | 2.3 (0.7 − 6.9) |
1Low-risk group: individuals carrying 0–1 risk genotypes; medium-risk group: individuals carrying 2 risk genotypes; and high-risk group: individuals carrying 3 or 4 risk genotypes.
2Adjusted for age, sex, and smoking and alcohol drinking status.